Beyond Virchow’s Triad: Does cardiovascular inflammation…
★★★☆☆ 3.0 — Peer reviewed, Vascular Medicine
★★★☆☆ 3.0 / 5 — Peer reviewed, Vascular Medicine
Beyond Virchow’s Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?
Gregory Piazza · 2015 · Vascular Medicine · article
Why this rating
- Evidence class: article (3.00)
- Cited 2.2x the field average (+0.25)
The rubric starts from what kind of study this is and lets citation data adjust it, never the other way round. Five stars is reachable by a well-regarded evidence synthesis and not by a single paper, however famous. Scores round down.
How the field treats it
26 citations recorded.
Field-weighted citation impact: 2.15. This is the count normalised against papers of the same age in the same field, where 1.00 is exactly average — it is the number worth reading, because a raw count means something different in oncology than in topology.
What stands against it
No retraction, correction or expression of concern on record.
No published comment, reply or rebuttal naming it was found among the works that cite it.
Data-integrity concerns often surface first on PubPeer, which cannot be read automatically: see its discussion there.
Notices from Crossref, which carries the Retraction Watch database; replies from OpenAlex.
What it actually says
Venous thromboembolism (VTE) has been traditionally considered a transient acute disorder requiring a limited duration of anticoagulant therapy. Patients who suffer deep vein thrombosis (DVT) or pulmonary embolism (PE) following major surgery, major trauma, or periods of immobility are generally treated with anticoagulation for 3–6 months. After completion of anticoagulation for the initial event, the risk of VTE recurrence is believed to return to that of the general population. However, epidemiological studies suggest that VTE may be better characterized as a chronic disorder with periodic relapses. While patients who suffer unprovoked (idiopathic) VTE bear the highest risk of recurrent events, exceeding 50% over 10 years if not treated with extended duration anticoagulation, those who suffer VTE in the setting of identifiable provoking factors have an enduring risk of recurrence that exceeds 20% over 10 years. 1 Randomized controlled trials of extended duration anticoagulation for prevention of recurrent unprovoked VTE have demonstrated that the rate of recurrence increases abruptly if anticoagulation is discontinued. 2 An analysis of the Danish National Registry of Patients demonstrated that patients with VTE have increased mortality over 30 years of follow-up and that recurrent PE is an important cause of death throughout this period. 3 The efficacy of extended duration anticoagulation for prevention of recurrent events after an initial unprovoked DVT or PE further supports the classification of VTE as a chronic relapsing disease. Prolonged anticoagulation with a low- (international normalized ratio (INR) target 1.5–2.0) 4 or conventional-intensity (INR target 2.0–3.0) 5 or a non-vitamin K-dependent oral anticoagulant such as rivaroxaban, 6 dabigatran, 2 or apixaba…
Read it
- Publisher record
- doi.org/10.1177/1358863x14568706
- OpenAlex record — the data this rating was computed from
This rates the paper, not the claim. A strong paper can still be irrelevant to, or misquoted by, the post that cited it. The stars say how much weight the study can bear — not whether it says what someone claimed it says.
Rubric v1.0 · data from OpenAlex, retrieved 19 Oct 2026